President
PTI - Pharmaceutical Technologies International
Dr. Metin Çelik is the founder and president of Pharmaceutical Technologies International, Inc. (PTI Inc.), with over three decades of global experience in pharmaceutical formulation, compaction science, and regulatory compliance. He has served as a consultant to more than 50 companies and as an expert witness in over 35 pharmaceutical patent litigations in the U.S. and Canada, providing technical insight on formulation, process, and regulatory matters.
Dr. Çelik is widely recognized for his pioneering contributions to tablet compaction and process design. He established the first two compaction simulators in the United States, transforming research and training in powder compression and scale-up. Before founding PTI in 1997, he worked with Novartis in Switzerland and Turkey, and later with Smith Kline & French Laboratories (now GSK), where he directed one of the earliest compaction simulator programs in the Western Hemisphere.
He has held academic appointments at Rutgers University, Near East University, and Eastern Mediterranean University, and currently serves as Adjunct Professor of Pharmaceutical Sciences at the University of New Mexico, mentoring graduate students and leading collaborative research in AI-driven formulation and process optimization.
At PTI, Dr. Çelik leads the integration of artificial intelligence, Quality by Design (QbD), Process Analytical Technology (PAT), and digital twin technologies into advanced pharmaceutical development. His current initiatives—such as the AI-Enabled Compaction–Coating Optimization and PAIex Pre-Approval Inspection Expert System—aim to modernize drug development and inspection readiness through intelligent data modeling.
An internationally recognized speaker, Dr. Çelik has delivered more than 300 invited presentations worldwide and has authored numerous publications, including serving as editor of a definitive book on tablet compaction. He is a founding and past chair of several AAPS Focus Groups, including Expert Systems and Excipients, reflecting his enduring leadership in science-driven and AI-enabled pharmaceutical innovation.